Loading…
← CockpitCompetitor Analysis › BLCO.TO Bausch + Lomb CorporationOpen in the cockpit ↗

Bausch + Lomb CorporationBLCO.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Medical Specialties

Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.

≈ A dedicated eye-care peer to Alcon/CooperCompaniesMomentum leader 98
Mkt cap
$7.41B
US dollars, full cap
Free float
11%
of shares outstanding
$/day
$74,952
20-day average traded
Fwd P/E
18.3×
forward earnings
ROIC−WACC
-3.0 pp
WACC 6.4%
Hurdle
+2 pp
Req g minus delivered
Official | Implied
B / B
agencies · bond market
Next earnings
98 days
24 Feb 2027
Close · CADC$30.03
1D-0.3%
1W-1.4%
1M+26.5%
3M+24.9%
6M+35.2%
YTD+28.1%
1Y+42.2%
ATR %2.2%
52w lowhigh2.0% off high

What Bausch + Lomb does

Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.

Is the same business as the New York line, listed on both exchanges. Contact lenses and eye-health products are repeat purchases, while surgical products, cataract equipment, are sold to clinics and hospitals. Bausch Health remains its controlling shareholder after the 2022 float.

In one line: A dedicated eye-care peer to Alcon/CooperCompanies.

Products and services

  • Contact lenses
  • Eye surgery devices/consumables
  • Eye care pharmaceuticals/OTC

Customers

  • Ophthalmologists/optometrists
  • Retail eye-care consumers
  • Hospitals/surgical centres

Where it sits in the supply chain

  • Medical devices/pharma
  • Eye health products
  • Contact lenses + surgical devices +…

What could go right

  • Contact lens/eye surgery volume growth (ageing population)
  • New product launches post spin-off

What could go wrong

  • Debt load from spin-off/parent relationship
  • Competitive contact lens/device pricing pressure

Moat: narrow (brand, scale, regulatory licence). Long-established Bausch + Lomb brand and broad regulatory approvals across contact lens and surgical device lines.

Headquarters: Vaughan, Canada / Bridgewater, New Jersey · Founded: 1853 · Employees: 13,000

Named competitors

Bausch + Lomb at a glance

Size Bausch + Lomb (BLCO.TO) is a Canada Health Care company (Medical Specialties) with a market value of $7.41B, the 89th largest of 405 Canada companies the cockpit tracks. Shares closed at C$30.03 on 18 Nov 2026.

Performance Over six months the shares gained 35.2%, against +28.4% for the median peer and +1.1% for the Canada market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 11.3% over the last twelve months (peer median +3.2%); the operating margin is 9.4% (peer median 16.9%).

Valuation It trades at 18.3× forward earnings against a peer median of 21.0× (6th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.0 points below its cost of capital (6.4% WACC).

Credit Bausch + Lomb has 1 bond outstanding ($1.40B), rated B by the agencies and trading like B at a weighted spread of 397 bp.

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BLCO.TO 135Peer median 129
Six months, rebased to 100: Bausch + Lomb against the median of its 20 peers (local-currency closes).

Bausch + Lomb financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$7.71BC$7.00BC$6.89BC$5.50BC$5.11B
Revenue growth—+2%+25%+8%—
Gross profitC$4.50BC$3.84BC$3.79BC$3.00BC$2.72B
EBITDAC$1.30BC$836MC$924MC$777MC$812M
Net income-C$158M-C$494M-C$456M-C$345MC$8.13M
Free cash flowC$359M-C$90.6M-C$84.9M-C$262MC$230M
Capital expenditureC$422MC$479MC$419MC$240MC$298M
Total debtC$7.25BC$7.20BC$7.10BC$6.20BC$3.46B

Quarterly statements and history in the cockpit →

Bausch + Lomb competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+25%+50%+75%+100%-10%0%+10%+20%GETI-B3008327747YPSN6869CTEC7701COHLNTHTFX688617GMEDBRKRPODDHAEBIOQGENDEMANTAVTRLIVNBLCO.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Bausch + Lomb is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×30×GETI-B3008327747YPSN6869CTEC7701COHLNTHTFX688617GMEDBRKRPODDHAEBIODEMANTLIVNBLCO.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bausch + Lomb is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%GETI-B30083277476869CTEC7701COHLNTHTFX688617GMEDBRKRPODDHAEBIOQGENDEMANTAVTRLIVNBLCO.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bausch + Lomb is the large dot.

Bausch + Lomb competitors and peer comparison

Head to head with its named competitors (BLCO.TO vs ALC.SW vs COO vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%18.3×12.0%
Alcon ALC.SW$36.9B+18%+1%12%21.5×12.2%
Cooper Companies (The) COO$11.6B-2%+5%19%13.4×9.4%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Carl Zeiss Meditec AFX.DE$3.17B+22%0%8%24.4×12.5%
Hoya 7741.T$49.0B-16%+13%32%27.7×14.1%
Menicon 7780.T$944M+26%+6%9%20.9×n/a
Santen Pharmaceutical 4536.T$4.14B+10%+2%16%16.7×-5.0%

How Bausch + Lomb compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bausch + Lomb against its 20 peers (data as of 18 Nov 2026)
MeasureBLCO.TOPeer medianRank in peer set
1-month return+26.5%+8.5%highest of 21
6-month return+35.2%+28.4%10th highest of 21
Distance from 52-week high-2.0%-7.2%4th highest of 21
Revenue growth (TTM)+11.3%+3.2%6th highest of 21
Operating margin9.4%16.9%2nd lowest of 21
Forward P/E18.3×21.0×6th cheapest of 21
Growth the price implies (Req g, 7 yrs)12.0%10.6%9th most demanding of 20
Growth delivered (Del g)+10.0%+9.3%9th highest of 20
Hurdle (Req g minus delivered)+2.0 pp+1.8 pp10th most demanding of 20
ROIC minus cost of capital-3.0 pp+3.4 pp5th lowest of 21
EV / EBITDA13.3×16.0×5th cheapest of 19
Net debt / EBITDA5.0×0.8×most indebted of 19
Bond spread397 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%

Bausch + Lomb bonds and credit

Bausch + Lomb has 1 bond outstanding with $1.40B face value. The agencies rate it B; its bonds trade like B. Weighted yield 8.71%, a spread of 397 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Bausch + Lomb's main competitors?
Named competitors: Alcon (ALC.SW), CooperCompanies (COO), Johnson & Johnson Vision (JNJ), Carl Zeiss Meditec (AFX.DE), Hoya (7741.T), Menicon (7780.T). The cockpit's measured peer set (industry) also includes Getinge (GETI-B.ST), Shenzhen New Industries Biomedical Engineering (300832.SZ), Asahi Intecc (7747.T), Ypsomed (YPSN.SW), Sysmex (6869.T), ConvaTec (CTEC.L).
Is Bausch + Lomb expensive compared with its peers?
On forward p/e it trades at 18.3× against a peer median of 21.0×, 6th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bausch + Lomb stock performed?
Over six months to 18 Nov 2026 the shares returned +35.2% against +28.4% for the median peer; over one year +42.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.